SARcode Bioscience eyes positive Phase III data for lead product
This article was originally published in Scrip
Executive Summary
The privately held biopharmaceutical company SARcode Bioscience has reported positive top-line Phase III data for its lead product, lifitegrast (SAR 1118), showing that it significantly improved symptoms of dry eye, as well as corneal staining, a marker of ocular surface damage that is a hallmark of chronic inflammation from dry eye disease.